Prolonged isolated thrombocytopenia, defined as recovery of other cell counts with continuous dependence on platelet transfusions for greater than 90 days after hematopoietic stem cell transplantation (HSCT), develops in approximately 5% of patients who undergo HSCT. Although the clinical conditions associated with prolonged isolated thrombocytopenia have been studied, a systematic review of bone marrow biopsies has not been performed and the pathophysiologic basis has not been defined. We reviewed all HSCT at one center from 1990 to 1995 (n = 454) and found 12 cases that met criteria for prolonged isolated thrombocytopenia (incidence = 12/454 or 3%). Bone marrow core biopsies from 12 patients with prolonged isolated thrombocytopenia were reviewed to determine cellularity, numbers of megakaryocytes, the presence of atypical forms, and clusters of megakaryocytes. These marrow megakaryocyte counts were compared to age and disease matched controls, and 11 normal donors. Patients (aged 1-56 years, mean 32 years) who underwent HSCT (four sibling HLA-identical, five autologous bone marrow, three autologous peripheral stem cell) with prolonged isolated thrombocytopenia had a statistically significant lower absolute megakaryocyte count in bone marrow biopsies performed before transplantation and more than 30 days after transplantation compared to control patients (aged 4 months to 50 years, mean 31 years) who underwent HSCT (four sibling HLA-identical, four autologous bone marrow, four autologous peripheral stem cell) for similar conditions. No apparent differences were seen in size of megakaryocytes, nuclear-cytoplasmic ratios, or clustering of megakaryocytes. Overall marrow cellularities were similar in the three groups. These findings suggest that decreased differentiation of megakaryocytes from stem cells, rather than ineffective platelet production or peripheral destruction of platelets, causes prolonged isolated thrombocytopenia in HSCT patients. Low megakaryocyte counts prior to HSCT may be a useful prognostic indicator, as this feature was associated with the development of prolonged isolated thrombocytopenia.
HSCT is used with increasing frequency for a variety of malignant and non-malignant disorders. 1 Early and late engraftment failure, as well as slow recovery of blood counts, are well-recognized complications of transplantation. [1] [2] [3] Prolonged isolated thrombocytopenia, defined as recovery of all other peripheral blood cell lines, but consistently low platelet counts after transplantation, is less well appreciated as an entity. The incidence varies from 5 to 20% of HSCT patients, depending on the degree (50 ϫ 10 9 /l to 150 ϫ 10 9 /l) [4] [5] [6] [7] and duration (60 days to 6 months) 5, 6 of thrombocytopenia. While the exact cause of prolonged isolated thrombocytopenia is not known, there are two main theories as to its origin. Normal platelets may be produced by the bone marrow, but prematurely destroyed in the peripheral circulation due to anti-platelet autoantibodies, splenic sequestration, or other factors. 5, 8 Alternatively, platelets may not be produced in sufficient numbers because of impaired megakaryocyte differentiation. 9 In previous studies relating to the pathogenesis of prolonged isolated thrombocytopenia, bone marrow biopsy findings have been incompletely evaluated or reported. [5] [6] [7] 10 In order to understand better mechanistically whether lack of production or peripheral destruction of platelets is the cause of prolonged isolated thrombocytopenia, we undertook a more detailed evaluation of bone marrow biopsies from affected patients. We report here the evaluation of pre-and post-transplant bone marrow biopsies from patients with prolonged isolated thrombocytopenia for overall cellularity, megakaryocyte number, and megakaryocyte abnormalities to determine factors which correlate with prolonged isolated thrombocytopenia.
Materials and methods
We reviewed blood bank records of all HSCT patients at University Hospitals of Cleveland over a 5-year period (April 1990 to March 1995; 454 transplants in 444 patients). Prolonged thrombocytopenia was defined as dependence on platelet transfusions for 90 or more days after transplantation. Medical records of these patients were reviewed; patients were excluded if they died or had disease recurrence within 90 days of transplantation or if they initially failed to engraft neutrophils Ͼ0.5 ϫ 10 9 /l. Biopsies from patients chosen for study that showed evidence of active disease (eg leukemia, metastatic cancer) were not included in the evaluation because of the likelihood that the disease would influence megakaryocyte number and/or morphology.
The slides were reviewed from all bone marrow biopsies performed within the time period 90 days before transplant (which includes the diagnosis and initial treatment for most patients) to 90 days after transplant (the time of expected engraftment). All biopsies outside of this time period were reviewed for those patients with 15 or fewer biopsies. Random biopsies before and after this time period were reviewed for patients with more than 15 additional biopsies.
Only bone marrow biopsies were used for evaluation of megakaryocytes because biopsies are considered to be a more accurate measure of megakaryocyte number than aspirate smears. 11 As biopsies in this institution are consistently performed using the same gauge needle and have a uniform width, the number of megakaryocytes per centimeter of length of each bone marrow biopsy was evaluated by one of the authors (MB). Areas of cartilage or cortical bone were not included in the measurement. The slides were then reviewed at ϫ10 to ϫ40 magnification and all the megakaryocytes were tallied. If several levels were available (eg more than one section per slide), the length measurement and tally were done on each level and a mean calculated. The number of levels varied from one to 12, with the mean number of levels being nine. Twenty percent of the patient biopsies were reviewed by a second author (NR) who was blinded as to the first author's counts and to the patient's status (control vs study patient). Evaluation of megakaryocyte morphology and the presence of clusters of megakaryocytes was also performed.
Biopsies from age-and disease-matched patients which were free of disease (control patients) and from allogeneic donors were similarly reviewed. Records for transfusion of red blood cells, random donor and apheresis platelets, and fresh frozen plasma were reviewed for all patients. The number of units transfused as well as the marrow megakaryocyte counts from the two patient groups (but not the normal marrow donors) were compared using the Mann-Whitney U test (Wilcoxon rank sum test), Correlation between the two pathologists' megakaryocyte counts was done using the Pearson coefficient of correlation.
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Results
From 454 HSCT patients, 12 subjects were identified who had prolonged isolated thrombocytopenia. A total of 82 bone marrow biopsies were reviewed from these 12 patients. Fifty-nine biopsies were reviewed from age-and disease-matched control patients who did not have prolonged isolated thrombocytopenia. Only one patient from each group had more than 15 biopsies which showed no evidence of disease. Not including these two patients, the mean number of biopsies per patient was 3.7 for control patients and 6.0 for study patients. Eleven biopsies from normal marrow donors were also reviewed.
Study patient and control patient characteristics and their respective preparatory regimens are shown in Tables 1A  and 1B . The study patients ranged in age from 1 to 56 years (mean, 32 years). There were six males and six females who received either HLA-identical allogeneic bone marrow transplants from siblings (four), autologous bone marrow transplants (five), or autologous peripheral stem cell transplants (three). The control patients were aged 4 months to 50 years (mean, 31 years); seven were male and five were female. In this group, there were four HLA-identical allogeneic bone marrow transplants from siblings, four autologous bone marrow transplants, and four autologous peripheral stem cell transplants. Each control patient had the same type of disease as their corresponding study patient, except that a control patient with chronic lymphocytic leukemia could not be found and so a patient with chronic myeloid leukemia was chosen.
The platelet count at the time of harvest for those patients who underwent autologous transplantation ranged from 62 to 224 ϫ 10 9 /l, mean 135 ϫ 10 9 /l in the study group. The control patients' platelet counts ranged from 76 to 306 ϫ 10 9 /l, with a mean of 176 ϫ 10 9 /l. Both allogeneic and autologous transplant recipients were evaluated at the time of transplantation. The study patients' platelet counts ranged from 7 to 247 ϫ 10 9 /l. The control patients' platelet counts ranged from 19 to 306 ϫ 10 9 /l. Evaluation of relative megakaryocyte size in the bone marrow biopsies revealed no significant differences. Within individual biopsies, the megakaryocytes often ranged from small to large. Apparent differences were not seen between the three groups (including normal donors) in number of nuclei per megakaryocyte. Abnormal forms or clusters were not identified in any of the biopsies that were included in the study.
Study patients used more cellular blood components than did control patients in the 90 days after transplantation ( Table 2 ). The use of single donor apheresis platelet units, random donor platelets and packed red blood cells was significantly lower in control patients. After 90 days post transplant, only two control patients received any blood components and all study patients required ongoing transfusions of red cells and platelets. The increased number of red blood cell transfusions in the study patients was usually associated with episodes of hemorrhage due to mucositis, cystitis, or gastrointestinal hemorrhage. Few fresh frozen plasma or cryoprecipitate transfusions were necessary in either group.
Megakaryocyte counts in normal donor marrow ranged from 63 to 208 megs/cm (mean 118 megs/cm) and overall bone marrow cellularity ranged from 30-72.5% (mean 58%) (Table 3) . In all time periods study patients were much more likely than control patients to have a lower absolute megakaryocyte count (expressed as number of megakaryocytes identified on H&E-stained section per cm of marrow space) ( Table 3) . Comparison of the megakaryocyte counts done by the two pathologists showed a correlation coefficient of 0.87.
Ninety days or more before transplantation, there was a significant difference between the two patient groups' megakaryocyte counts, with study patients already demonstrating a lower megakaryocyte count; however, there was no significant difference in cellularity. The biopsies from 90 days to 30 days before transplantation showed significant differences for both cellularity and megakaryocyte count. The study patients had higher overall cellularity, but lower megakaryocyte counts. The marrow megakaryocyte count was again significantly lower in the study patients from 30 days prior, to the time of transplantation, with no significant difference in cellularity between the two groups.
In the immediate post-transplant time period, there was no difference in cellularity or megakaryocyte count. From 30 days to 90 days post transplantation, both megakaryocyte count and cellularity were significantly lower in the study patients. The megakaryocyte count remained significantly lower in the study group after 90 days post transplantation, but the cellularity was similar in the two groups during the same period (Table 3) .
Samples of the progenitor cells obtained from 11 control patients and eight study patients were assayed for CFU-GM, BFU-E and CFU-GEMM. Comparison of the number of transfusions of different blood components between the two patient groups from the day of transplantation until 90 days after transplantation. SDP = single donor apheresis platelet; RDP = random donor platelet; RBC = packed red blood cell; FFP = fresh frozen plasma.
differ statistically between these two groups, but data were not available for the remaining patients.
Six study patients died 4 months to 2 years after transplantation (two from infections, one each from tumor recurrence, cerebral hemorrhage, cardiac arrest, and one of unknown cause). One control patient died a year after transplantation from infection.
Discussion
In this study, we found that in 12 of 454 (3%) HSCT patients, platelet transfusion independence took more than 3 months, despite recovery of both myeloid and erythroid cell lines. Bone marrow biopsies performed in these patients before and after transplantation showed that the number of megakaryocytes was significantly lower than in biopsies obtained from transplant patients who did not have prolonged isolated thrombocytopenia.
Previous studies regarding prolonged isolated thrombo- Bone marrow biopsies for study and control patients, organized according to the day they were done relative to the day of transplantation (T0). Values for normal donors are listed at the top for comparison.
cytopenia after transplantation indicate that megakaryocytes were decreased or absent in biopsies from some patients after transplantation. 5, 10 Most reports, however, do not attempt to quantitate megakaryocyte numbers, examine morphology, or correlate megakaryocyte numbers in preand post-transplant specimens with thrombocytopenia. Sheridan and co-workers 7 compared patients who received autologous bone marrow with G-CSF-mobilized peripheral stem cell transplants (study patients) with patients who received bone marrow transplants with G-CSF administered after transplantation and patients who underwent bone marrow transplantation who received no G-CSF. They described megakaryocyte numbers within or above the 'normal' range in seven of 11 study patients vs one of 27 control patients. In other words, the patients who did not have G-CSF-mobilized transplants had lower megakaryocyte counts. 7 Pendry et al 10 performed a semiquantitative analysis of megakaryocytes in bone marrow biopsies (scoring 0-3) and found that megakaryocytes were more likely to be absent 35 days after transplant in patients with delayed platelet recovery after transplant. Klumpp and associates, 14 in discussing three cases of cytopenia after transplantation, described one patient with prolonged isolated thrombocytopenia who was found to have plateletassociated antibodies. They suggested that prolonged thrombocytopenia might be associated with either hypocellular marrows or antibodies directed against which ever cell line failed to recover.
14 In a mouse model, Bradford et al 15 found decreased platelet counts at 30 days post transplant. The platelet counts recovered by 90 days after transplantation; the counts of CFU-Meg, however, remained low even at 270 days post-transplant. 15 Not all studies have shown decreased megakaryocytes in patients with prolonged isolated thrombocytopenia. Sivaku-maran and colleagues 5 described five patients with prolonged thrombocytopenia yet only one patient had decreased numbers of megakaryocytes. The other four subjects were found to have 'normal' numbers of megakaryocytes, but also had HLA or platelet-associated antibodies. 5 Quantitative evaluation of megakaryocytes, however, was not performed in any of these studies.
Few transplant studies quantitate the number of megakaryocytes in either normal or abnormal bone marrow specimens. Some studies have focused on the use of flow cytometry or special handling such as saponin lysis with microfiltration of bone marrow aspirates to assess megakaryocyte content. 16, 17 Thiele et al 18 examined bone marrow biopsies stained immunohistochemically with antibodies to CD 61 (gpIIIa). In addition to a group of control patients, megakaryocytes were evaluated in biopsies from patients who had reactive thrombocytosis and thrombocytopenia. All patient groups, regardless of their platelet count, had megakaryocyte numbers that were higher than those for control patients. This finding is in contrast to our data in which both study and control patients had lower megakaryocyte counts than the normal marrow donors. The control patients in the study by Thiele et al, 18 however, were not normal marrow donors, but patients with mild osteoporosis and normal platelet counts.
Many factors have previously been associated with prolonged thrombocytopenia, including a low platelet count at the time of hematopoietic stem cell collection, total body irradiation, use of cryopreserved cells, 10 use of myeloid growth factors after transplantation, 19 lack of myeloid growth factor mobilization of peripheral blood stem cells, 7, 20, 21 decreased number of mononuclear cells harvested, bone marrow involvement by disease, 4 use of busulfan, 22 in vitro bone marrow purging, 23 older age of patients, 24 a diagnosis of acute non-lymphocytic leukemia, 24 fever and veno-occlusive disease. 25 These studies show that many of these factors are associated with poor overall engraftment. Our study indicates that low numbers of megakaryocytes in pre-harvest samples may be predictive of prolonged thrombocytopenia after transplantation in patients who recover all other cell lines.
Our findings suggest that impaired megakaryocyte differentiation, despite maturation of other cell lines, is responsible for prolonged isolated thrombocytopenia in HSCT patients. Careful evaluation of the megakaryocyte content of bone marrow biopsies at the start of transplantation might predict which patients are at increased risk for prolonged thrombocytopenia.
Lack of megakaryocyte differentiation in patients with prolonged thrombocytopenia may be due to a relative deficiency of the cytokine thrombopoietin which may be the result of damage to the cells responsible for thrombopoietin production. Alternatively, resistance to thrombopoietin in the marrow stem cells or megakaryocyte progenitors may be the problem. Further studies are warranted to better define the potential use of recombinant thrombopoietin in HSCT patients with prolonged thrombocytopenia. 26, 27 Although relatively uncommon (3% in our series), prolonged thrombocytopenia is a significant problem because of the associated morbidity and mortality as well as the massive transfusion support that these patients require. The study patients in this series used more than 10 times the number of cellular blood components than did the control patients. Simple techniques that could be used to predict which patients might be at risk for prolonged thrombocytopenia, such as we have described here, would be beneficial for both patient counselling and medical management. A more precise definition of prolonged isolated thrombocytopenia and its contributing factors might also clarify its etiology and lead to its prevention or treatment. Ultimately, patients with prolonged isolated thrombocytopenia would probably be excellent candidates to receive recombinant thrombopoietin. 27 
